Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 718 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by levelWhat for?
by area of lawAll areas of law
Who?
by company- Purdue Pharma L.P. €4.75bn 95 % · 1 case
- Gilead Sciences, Inc. €177.8m 4 % · 1 case
- Dompé U.S. Inc. €27.5m 1 % · 1 case
- SCG Plastics Co., Ltd. €18.8m 0 % · 1 case
- Takeda Pharmaceuticals U.S.A., Inc. €11.7m 0 % · 1 case
- EyePoint Pharmaceuticals, Inc. €4.08m 0 % · 1 case
- Unicat Catalyst Technologies, LLC €3.35m 0 % · 1 case
- AFCO (Tochtergesellschaft der Zep Inc.) €157,452 0 % · 1 case
- Guangxi Kelun Pharmaceutical Co., Ltd. — 0 % · 1 case
- Henkel AG & Co. KGaA — 0 % · 1 case
- 1 more€0
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 0 | — |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 0 | — |
| Q1 2025 | 0 | — |
| Q2 2025 | 1 | €177.8m |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 0 | — |
| Q3 2026 | 0 | — |
1 case
28 Apr 2025 Gilead Sciences, Inc.Gilead: 202 million USD – speaker programmes with fees, luxury meals and travel €177.8m
Gilead paid physicians who spoke at or attended events on its HIV medicines fees, meals and travel expenses to promote prescriptions; high prescribers received hundreds of thousands of dollars, and events took place at luxury restaurants. The court-approved settlement of 202 million USD contains extensive admissions of fact.
Selecting speakers by prescription volume turns continuing education into bribery – selection criteria and hospitality limits must be documented.
Fees and hospitality at professional events
- Authority / court
- U.S. Attorney's Office, Southern District of New York; U.S. District Court (S.D.N.Y.)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Published
- 29 Apr 2025
Original amount 202,000,000 USD, converted at the ECB reference rate of 28 Apr 2025.
- HHS-OIG Enforcement Actions: U.S. Attorney Announces $202 Million Settlement With Gilead Sciences … Speaker Programs (29.04.2025) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link